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Severe acute respiratory syndrome coronavirus-2 (SARS-
CoV-2) is the novel coronavirus first detected in Wuhan,
China. It causes an infection named coronavirus disease
2019 (COVID-19), and is now spreading worldwide. Cur-
rently, there are no approved treatment options in Europe
and there is no available vaccine. Reports from China,
Europe, and USA suggest a high mortality rate and stret-
ched intensive care unit (ICU) capacity [1–3]. It has been
found that the main risk factors for death are obesity,
hypertension, diabetes, male gender, and older age. More-
over, Liang et al. reported that 1% of COVID-19 patients
had a history of cancer, higher than that of the overall
Chinese population (0.29%), with lung cancer being the
most frequently found. Moreover, patients with cancer
seemed to have a higher risk of severe events (ICU
admission, need of assisted ventilation, death), reaching
39% versus 8% in those not suffering from a neoplasia [4].
Their study suggests that hospital admission and recurrent
outpatient visits, inherent to cancer patients’ management,
are potential risk factors for SARS-CoV-2 infection.
Another aspect which may probably be even more relevant
in cancer patients is their inability to receive the necessary
care in time, under the changed scenario of a viral pandemic
management.
Scarce data are available on patients with hematological
malignancies. Although some recommendations for
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management of those with solid cancer and hematologic
neoplasms have been published, more practical guidelines
may be required for individual types of malignancies [5].
Particularly acute leukemia (AL) patients who suffer from a
profound and long-lasting humoral and cellular immune
deficiency [6], may benefit from tailored recommendations.
Moreover, AL patients under intensive chemotherapy are at
a high risk of requiring ICU care, and of mortality in case of
complications [7]. Therefore, special attention should be
paid to this specific population during the ongoing COVID-
19 outbreak. Here, we summarize some recommendations
to help AL patients’ management in the current situation.
The aims are to minimize the requirement for ICU admis-
sion, without compromising the patient’s chance of being
adequately treated.
General principle
Patients should be aware of their frailty to COVID-19
infection and specific hygiene measures and importance of
social distancing should be explained.
All journeys outside the hematological department
should be discussed and adapted for the situation. For
example, it should be ensured that outpatient transportation
services bring patients to the scheduled time of their con-
sultation, in order to minimize the time spent in the waiting
area. For those requiring oral or subcutaneous treatment
administration, one needs to minimize hospital visits. Pos-
sible strategies for this are offering telephone or video
consultations, cutting nonessential face-to-face follow-up,
using home-delivery services for medicines, and using local
services for blood tests.
Screening
Given that percentage of asymptomatic cases of COVID-19
can be high [8], all newly diagnosed patients with acute
myeloid leukemia (AML) or acute lymphoblastic leukemia
(ALL) should be screened for COVID-19 infection by PCR
and high-resolution thoracic computerized tomography scan
before initiating chemotherapy [9] (Table 1). The screening
should be repeated before each course of chemotherapy. If
positive, the decision to initiate or continue the treatment
needs to made on a case-by-case basis.
Clinical research
In terms of clinical research, most clinical trials have been
suspended during the pandemic. However, in some cases,
clinical trials allow access to off-label drugs or combina-
tions which can be highly beneficial. For patients already
included in clinical trials, their participation should, in
principle, continue. Nevertheless, the patients’ safety must
remain the priority and, similarly to the recommendation for
those treated outside clinical trials, outpatient visits must be
replaced by e-health assessment whenever possible. Fur-
thermore, for those receiving oral treatment in the frame of a
clinical trial, most clinical research organizations now
organize home delivery of the investigated medication to
Table 1 Recommendation for
management of patients with
acute leukemia during the
COVID-19 outbreak.
General points
● Screening for COVID-19 infection before initiating chemotherapy.
● Cytogenetics and molecular biology should be awaited before starting treatment.
● MRD molecular remission should be useful to consider omitting one cycle of consolidation.
● Outpatient visits should be as much as possible deferred or substituted with telemedicine visites.




Induction: “3+7” should be
considered
Consolidation: cytarabine should be
reduced to 1.5 mg/m2




Azacytidine or low dose of cytarabine in monotherapy,
hydroxycarbamide, palliative care




Discuss indication for allo-HCT on case-by-case.
Nonurgent allo-HCT should be deferred as much as possible.
High-risk allo-HCT such as for refractory AL or patient with a high risk of NRM should not
proceed.
ALL acute lymphoblastic leukemia, Allo-HSCT allogeneic stem cell transplantation, AML acute myeloid
leukemia, MRD measurable/minimal residual disease, “3+ 7” daunorubicin and cytarabine.
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avoid hospital visits. Alternatively, hospital pharmacies
should be authorized to deliver 2 or 3 months’ worth of
medication, rather than the standard one. Whenever possi-
ble, follow-up by e-health assessment should be preferred to
avoid hospital visits.
Acute myeloid leukemia
Patients fit to receive intensive therapy
For patients with favorable or intermediate risk acute
myeloid leukemia (AML) [10] who are fit to receive
intensive chemotherapy, the standard “3+ 7” induction
should be considered [11]. For AML with FLT3ITD
mutation, midostaurin may be added to induction and
consolidation as it prolongs OS and EFS [12].
For consolidation, the dose of cytarabine could be
reduced to 1.5 g/m2 instead of 3 g/m2 for all patients.
Indeed, prospective studies showed that consolidation, in
association with anthracycline, with either intermediate or
high dose of cytarabine, did not result in significant dif-
ferences in the 5-year overall survival, whereas prolonga-
tion of neutropenia and higher transfusion demands were
observed in the high dose cytarabine arm [13–15]. The use
of G-CSF should be recommended after each cycle to
reduce the duration of neutropenia. In patients who have
negative measurable/minimal residual disease (MRD) after
two cycles of chemotherapy, omission of the fourth cycle of
consolidation should be discussed. In this case, the MRD
should be very closely monitored, and maintenance therapy
considered, especially in those cases.
Patients with an adverse cytogenetic risk should receive
intensive therapy if a real chance of going to allogeneic
stem cell transplantation exists.
In the case of acute promyelocyte leukemia (APL),
chemotherapy should be initiated without delay. Patients
with standard-risk APL (white blood cells <10 × 109/L)
should receive all-trans-retinoic acid (ATRA) and arsenic
trioxide (ATO) as frontline following the standard guideline
for APL management (i.e., avoidance of G-CSF for the risk
of differentiation syndrome). For high-risk APL, induction
should be performed with idarubicine, ATRA, and ATO.
Patients unfit to receive intensive therapy
Newly diagnosed patients with AML, who are unfit for
intensive treatment, hypomethylating agents (HMA) or low-
dose cytarabine monotherapy (LDAC) could be given in the
case of no-proliferative disease. The addition of venetoclax
should be discussed on a case-by-case basis, considering the
positive impact on CR rate and OS in combination with
HMA or LDAC, but also the risk of tumor lysis syndrome
and myelosuppression (https://www.fda.gov/drugs/fda-a
pproves-venetoclax-combination-aml-adults). After the first
cycle with this combination, if medullary blast infiltration is
<5%, dose adjustments, duration of venetoclax, and/or the use
of G-CSF are recommended to avoid prolonged cytopenia.
Taking into account age, comorbidities, and disease char-
acteristics, patients could also be managed with supportive
care and, possibly, eventually hydroxycarbamide.
For patients with relapsed or refractory AML, each team
should carefully assess the risks and benefits of pursuing a
curative approach on a case-by-case basis. Molecular tar-
geted therapy (e.g., enasidenib, ivosidenib, sorafenib, gil-
teritinib, etc.) should be discussed, considering the rate of
complete remission and the duration of the response that
can be expected, with a view to postponing an intensive
treatment or allogeneic hematopoietic cell transplantation
(allo-HCT).
Acute lymphoblastic leukemia
In ALL, one major question is the use of glucocorticoids, as
they remain essential components of ALL therapy. They
appeared to be effective in reducing immunopathological
damage [16], but there are concerns about their possible
promotion of viral rebound and adverse events. Taking into
account the major role of glucocorticoids in the treatment of
ALL, and the paucity of information on their potential
negative role in COVID-19 infections, physicians should
use the recommended dose of glucocorticoids, especially
during, the prephase, induction, and consolidation, with a
major concern on preventing bacterial and fungal infections.
The use of asparaginase should be carefully monitored
considering the inherent risk of thrombotic complications of
this drug, especially knowing that COVID-19 can lead to
systemic coagulation disorders, and thrombotic complica-
tions. The use of blinatumomab or inotuzumab should not
be delayed as their benefit in terms of survival has been
established.
For Philadelphia-chromosome positive ALL, inhibitors
of tyrosine kinase should be maintained considering their
positive impact on OS and EFS.
Stem cell transplantation
The EBMT recommendations for management of allo-HCT
during the COVID-19 outbreak have been recently pub-
lished [17]. Nonurgent allo-HCT procedures should be
deferred as much as possible. Due to the rapidly changing
situation, access to a stem cell donor may be restricted by
the fact that the donor may become infected at the harvest
centers in the middle of a strained health care system, or by
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travel restrictions across international borders. It is, there-
fore, strongly recommended to have secured stem cell
product access, by cryopreserving the product before the
start of conditioning. In situations when this is not possible,
an alternative back-up donor should be identified. The
impact of COVID-19 on a timely graft availability, on
cellular therapy unit organization, and on ICU capacity
should be considered for each patient with allo-HCT indi-
cation. It is necessary to highlight the yet unknown impact
of COVID-19 infection on outcomes, when counseling
patients on the benefits and risks of the allo-HCT procedure.
All patients who have a high risk of disease progression
without allo-HCT should still be considered candidates for
the procedure according to standard clinical practice. More
controversial allo-HCT indications such as refractory AL, or
patients with a high risk of non-relapse mortality should be
avoided.
Overall, the management of patients with AL in the
COVID-19 outbreak is a major challenge, as this hemato-
logical malignancy requires rapid treatment, which may
result in a requirement for admission to an ICU unit. Phy-
sicians should therefore carefully balance the risk of
COVID-19 infection itself against the benefit of antileu-
kemic intensive treatment on a case-by-case basis, within
the individual resources of each medical institution.
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